Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 7/20 | 1.00 |
| ▸ | EDNRB | P24530 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bms-182874 SCHEMBL117150 | 0.99 | EDNRA (0.98) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7949156 | 0.90 | EDNRA (0.81) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7857311 | 0.88 | EDNRA (1.00) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL6767574 | 0.87 | EDNRA (0.77) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7860473 | 0.87 | EDNRA (0.77) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL8784615 | 0.86 | EDNRA (0.76) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7949496 | 0.86 | EDNRA (0.76) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7939545 | 0.85 | EDNRA (0.74) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7951138 | 0.85 | EDNRA (0.74) | EDNRAEDNRBKDM4EMEN1CYP3A4 | |
| SCHEMBL7946125 | 0.85 | EDNRA (1.00) | EDNRAEDNRBKDM4EMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | claimed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| EP-0558258-B1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-05-07 | — | — | EP | claimed |
| EP-0558258-A1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-09-01 | — | — | EP | claimed |
| JP-6009585-A | — | — | None | — | — | JP | disclosed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| US-20170298105-A1 | Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist | MIDWESTERN UNIVERISTY | 2017-10-19 | — | — | US | disclosed |
| US-20170298105-A1 | Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist | MIDWESTERN UNIVERISTY | 2017-10-19 | — | — | US | disclosed |
| US-9493524-B2 | Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist | MIDWESTERN UNIVERSITY (US) | 2016-11-15 | — | — | US | disclosed |
| WO-1996019233-A2 | IRRIGATION SOLUTION AND METHOD FOR INHIBITION OF PAIN, INFLAMMATION AND SPASM | OMEROS MEDICAL SYSTEMS, INC. (US) | 1996-06-27 | — | — | WO | disclosed |
| EP-0714391-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996015125-A1 | NONPEPTIDE ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1996-05-23 | — | — | WO | disclosed |
| US-5482960-A | Nonpeptide endothelin antagonists | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
| WO-1995005376-A1 | SUBSTITUTED 2(5H)FURANONE, 2(5H)THIOPHENONE AND 2(5H)PYRROLONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1995-02-23 | — | — | WO | disclosed |
| US-5378715-A | Sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1995-01-03 | — | — | US | disclosed |
| JP-H069585-A | SULFONAMIDE ENDOTHELIN ANTAGONIST | E R SQUIBB & SONS INC | 1994-01-18 | — | — | JP | disclosed |
| EP-0558258-A1 | N-isoxazole-naphthylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | EDNRA 429/4885EDNRB 502/4885KDM4E 4229/4885 |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885KDM4E 1117/4885 |
| US-20170298105-A1 | Methods for Treatment of Stroke or Cerebrovascular Accidents Using an ETB Receptor Agonist | EDNRB, EDNRA, ADRA2B | EDNRA 2/4885EDNRB 1/4885KDM4E 4287/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885KDM4E 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.